Evidence map›Paper›PMID 21787755›Full record

ReviewBiochemical pharmacology2011

Naturally-expressed nicotinic acetylcholine receptor subtypes.

Jie Wu, Ronald J Lukas

Open access · greenAbstract readReview
In one paragraph

Review in Biochemical pharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?International journal of molecular sciences · 2021
    Review
  18. Translational Research in Nicotine Addiction.Cold Spring Harbor perspectives in medicine · 2021
    Review
  19. Article
  20. Review

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jie WuDivision of Neurology, Barrow Neurological Institute, 350 West Thomas Road, Phoenix, AZ 85013, United States. jie.wu@chw.edu
Ronald J Lukas
Barrow Neurological Institute · US

Funding

Design and Study of New Nicotinic Analogs for Use in DepressionU19MH085193 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KOZIKOWSKI, ALAN P. · 2009 to 2013
$4.5M
Synthesis of Bupropion Analogs, Including Possible Metabolites and 3-PhenyltropanU19DA019377 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI DAMAJ, M. IMAD · 2005 to 2009
$3.4M
Molecular Bases for Effects of NicotineR01DA015389 · NIDA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI LUKAS, RONALD J · 2003 to 2007
$1.6M
HOMOMERIC NICOTINIC ACETYLCHOLINE RECEPTORSR01NS040417 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI LUKAS, RONALD J · 2000 to 2002
$1.2M
Variants in CHRNA5/CHRNA3/CHRNB4 and nicotine dependenceR21DA027070 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI CHEN, XIANGNING · 2009 to 2010
$897k
Construction and Expression of Concatemeric alpha6beta2* Nicotinic Acetycholine RR21DA026627 · NIDA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI WHITEAKER, PAUL · 2009 to 2010
$407k
Tunable Nicotine DNA-NanovaccinesR21DA030045 · NIDA · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI CHANG, YUNG · 2011 to 2012
$362k
HTS Assay Development for alpha6/3beta2beta3 Subtype Nicotinic ReceptorsR21DA032483 · NIDA · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI WHITEAKER, PAUL · 2011 to 2011
$254k
NIDA NIH HHS R01 DA015389NIDA NIH HHS R21 DA026627NIDA NIH HHS R21 DA027070NIDA NIH HHS R21 DA030045NIDA NIH HHS R21 DA032483NIDA NIH HHS U19 DA019377NIMH NIH HHS U19 MH085193NINDS NIH HHS R01 NS040417
6 · The paper itself

Abstract

Nicotinic acetylcholine receptors (nAChRs) warrant attention, as they play many critical roles in brain and body function and have been implicated in a number of neurological and psychiatric disorders, including nicotine dependence. nAChRs are composed as diverse subtypes containing specific combinations of genetically-distinct subunits and that have different functional properties, distributions, and pharmacological profiles. There had been confidence that the rules that define ranges of assembly partners for specific subunits were well-established, especially for the more prominent nAChR subtypes. However, we review here some newer findings indicating that nAChRs having largely the same, major subunits exist as isoforms with unexpectedly different properties. Moreover, we also summarize our own studies indicating that novel nAChR subtypes exist and/or have distributions not heretofore described. Importantly, the nAChRs that exist as new isoforms or subtypes or have interesting distributions require alteration in thinking about their roles in health and disease.

Indexed as

Receptors, NicotinicAnimalsBrainHumansProtein SubunitsTobacco Use DisorderProtein SubunitsReceptors, Nicotinic

Identifiers

PMID21787755
PMCPMC3163308
OpenAlexW2074227215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.